StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Great volume and sp swing

<< Previous

Bullboard Posts

Next >>

Comment by Thehuntsmanon Aug 12, 2020 10:26pm

133 Views

Post# 31401354

RE:Great volume and sp swing

Awesome run down Northern. Big Boo ya here.

Northerencents wrote:
Looking very bullish here, with many stocks this would be a Homerun to some...with szls this is just the tip of the iceberg

let's not forget
medmira: trading at 400 million Mc based on covid revenue with no revenue

Sona nano: trading at 500 million Mc and was pushing a 1 billion based on speculative Covid revenue and has zero

lexagene: 100 million Mc based on speculative revenue but has zerp

the list goes on and on.

And here we are

Stagezero life sciences: was sitting at a 23 million Mc and today's action put us up to 35 million Mc with no previous speculative covid revenue valuation, but the kicker we are currently receiving revenue and ramping up with Aristotle the 10 panel cancer test in our back pocket!

It is no wonder, why the recent coverage is targeting .67 cents for a Mc of 260 million ish

It should be there just on speculation in this industry let alone when some concrete numbers come out.

well today deserves a Boo Ya at the very least

cheers